Spine Biologics Market to Exceed $3.5 Billion by 2031

The global spine biologics market is primed for solid growth over the next eight years. 

Transparency Market Research predicts the sector will grow 4.2% annually through 2031 to reach $3.5 billion in total value. The market is expected to expand 4.1% this year to reach $2.5 billion, up from a $2.4 billion value last year, Transparency Market Research data suggests.

Key growth drivers include the world’s aging population, a preference for minimally invasive procedures, the rise in degenerative spine disorders, and surge in treatment costs. Biologics and their varied benefits—faster recovery, minimal postoperative time, and the ability to activate cellular growth—also is helping advance the spine biologics sector. Many companies have been focusing on developing technologically advanced and cost-effective products to gain a competitive advantage. In 2018, for example, NuVasive Inc. expanded its biologics business line by launching the AttraX Scaffold. 
 
The development and commercialization of advanced stem cell therapies are also bolstering the market. Stem cells have shown promising potential in promoting tissue regeneration and improving patient outcomes in spinal fusion surgeries. Various companies have developed bone graft substitutes using biologic materials; in 2021, Medtronic offered INFUSE Bone Graft, which utilizes a recombinant human bone morphogenetic protein (rhBMP-2) to stimulate bone growth in spinal fusion surgeries. This product eliminates the need for harvesting bone from the patient’s body and has shown positive clinical outcomes.
 
The adoption of these bone graft substitutes is increasing, as these offer advantages such as ease of use, reduced risk of infection, and improved patient outcomes. Research and development efforts are focused on enhancing the efficacy and safety of spine biologics, which is expected to provide opportunities for companies to develop novel products and therapies during the forecast period.
 
By product, bone allograft-based spine biologics are likely to gain significant momentum until 2033. By end user, hospitals are expected to remain the primary site for conducting spine biologics.

According Transparency Market Research data, North America accounted for a significant share of the global market in 2022. This is ascribed to large geriatric population, increase in adoption of minimally invasive procedure, and rise in prevalence of spine disorders such as spondylolisthesis, spinal stenosis, and disc-related issues.
 
According to the American Association of Neurological Surgeons, an estimated 17,000 new cases of spinal cord injury are reported in the U.S. every year. Thus, a large spinal cord injury population is likely to drive demand for treatment of disorders, wherein spinal biologics plays an important role in diagnosis.
 
Asia Pacific is expected to witness significant spine biologics market expansion during the forecast period due to an increase in the region’s geriatric population, the increasing prevalence of spinal disorders, the growing healthcare infrastructure, and improved access to advanced spinal treatments in countries such as China, India, and Japan.
 
The spine biologics landscape is characterized by the presence of a substantial number of established market players. They include: Depuy Synthes, Orthofix Medical Inc., Stryker Corporation, Zimmer Biomet, Arthrex Inc., Exactech Inc., Spine Wave Inc., Medtronic plc, NuVasive Inc., PUR Biologics (HippoFi Inc.), and Bone Biologics Corporation.
 
Key Market Developments

• In April 2023, PUR Biologics, a subsidiary of HippoFi Inc., launched PURcore, a moldable synthetic with an interconnected micro-pore structure for spine surgery. PURcore allows for the rapid colonization of the patient’s own cells and growth factors which promotes bone regeneration and healing.
• In February 2022, Orthofix Medical Inc. expanded the full market launch of Opus BA, a synthetic bioactive bone graft solution for cervical and lumbar spine fusion procedures. Furthermore, Opus BA can be used to fill bone voids or gaps in the skeletal system that are not intrinsic to the stability of bony structure.
• In April 2023, Bone Biologics Corporation received approval from the Human Research Ethics Committee (HREC) for the first of a planned multicenter pilot clinical trial to evaluate the company’s NB1 bone graft in Australia. This pilot study will evaluate the safety and effectiveness of NB1 in 30 adult subjects who undergo transforaminal lumbar interbody fusion (TLIF) to treat degenerative disc disease (DDD).